The use of N-acetylcysteine in the prevention of hangover: a randomized trial.
Level 2 - randomized trial
Individual randomized controlled crossover trial
PubMed 34183702 · doi:10.1038/s41598-021-92676-0
What was done
Forty-nine volunteers participated in a randomized, double-blind, placebo-controlled crossover study where they consumed beer to reach a breath alcohol content of 0.1 g/210L on two separate occasions. Participants received either low-dose N-acetylcysteine (NAC, 600–1800 mg) or placebo during the first encounter and the opposing treatment during the second. The following morning, subjective hangover severity was assessed using the Hangover Symptom Scale Questionnaire, analyzing within-subject differences between treatments.
What was found
There was no significant difference in the distribution of total hangover scores between NAC (score of 10) and placebo (score of 13) (P = .45), nor in individual hangover symptoms overall. Subgroup analysis by sex showed a statistically significant difference in total hangover difference scores (P = .04; female -3.5 vs. male 2), specifically for nausea (P = .05) and weakness (P = .03), indicating lower symptom scores with NAC among female participants.
Why it matters
Despite the common use of NAC as an over-the-counter hangover remedy, this trial shows no general benefit for alcohol hangover mitigation. The observed sex-specific effects provide a narrow hypothesis for future research rather than evidence for clinical use.
Limits
The sample size was small (n = 49), and alcohol exposure was restricted to a controlled breath alcohol level of 0.1 g/210L using beer only, which may not reflect real-world heavy or mixed-alcohol consumption. The wide dosing range (600–1800 mg) was not broken down into separate dose-response analyses in the abstract, and the sex-specific finding was an exploratory subgroup outcome susceptible to type I error.
Cited by
- supports A placebo-controlled trial found that N-acetylcysteine did not significantly reduce overall hangover symptoms in humans, though subgroup analysis suggested potential reduction of nausea and weakness in women.